<DOC>
	<DOCNO>NCT00746694</DOCNO>
	<brief_summary>The objective trial study management PPE participant metastatic ovarian breast cancer treat Caelyx , determine frequency use pharmacological treatment ( preventive therapeutic ) PPE compliance educational recommendation PPE .</brief_summary>
	<brief_title>A Study Determine Management Palmar-plantar Erythrodysesthesia ( PPE ) Patients With Metastatic Ovarian Breast Cancer Treated With Caelyx ( Study P05020 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Paresthesia</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Women 18 year age old . Participants metastatic breast ovarian cancer receive treatment pegylated liposomal doxorubicin . Participants give write consent . Participants currently participate clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>